Holen Sie sich die Stockscreener-App
0.79
10.37%
-0.0914
Handel nachbörslich:
.87
0.08
+10.13%
Renovorx Inc Aktie (RNXT) Neueste Nachrichten
RenovoRx stock hits 52-week low at $0.77 amid market challenges - Investing.com
HC Wainwright Reaffirms “Buy” Rating for RenovoRx (NASDAQ:RNXT) - Defense World
H.C. Wainwright maintains Buy rating on RenovoRx stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on RenovoRx stock - Investing.com Australia
Revolutionary Pancreatic Cancer Treatment Update: RenovoRx CEO Presents Latest Clinical Trial Results - Stock Titan
RenovoRx Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RenovoRx projects growth with new orders and clinical trial - Investing.com
RenovoRx Hits Major Milestone: First Revenue from Cancer Device as Phase 3 Trial Nears Key Analysis - Stock Titan
RenovoRx, Inc. SEC 10-K Report - TradingView
RenovoRx Delays Yearly Report Filing - TipRanks
Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - Business Wire
RenovoRx (RNXT) to Release Earnings on Monday - Defense World
HC Wainwright Estimates RenovoRx FY2024 Earnings - Defense World
RenovoRx Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting - BioSpace
Breakthrough: RenovoRx's Pancreatic Cancer Treatment Shows Promise with Reduced Systemic Exposure - Stock Titan
RenovoRx (NASDAQ:RNXT) Coverage Initiated by Analysts at HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of RenovoRx (RNXT) with Buy Recommendation - Nasdaq
HC Wainwright Initiates Coverage on RenovoRx With Buy Rating, $3 Price Target - MarketScreener
RenovoRx honored for cancer treatment research By Investing.com - Investing.com South Africa
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting - BioSpace
RenovoRx honored for cancer treatment research - Investing.com
RenovoRx (NASDAQ:RNXT) Stock Price Up 11.5% – Should You Buy? - Defense World
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET - Business Wire
RenovoRx Reveals Commercial Milestones and Phase 3 Trial Updates for Revolutionary Pancreatic Cancer Treatment - Stock Titan
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025 - Business Wire
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026 - Business Wire
RenovoRx launches public stock offering - MSN
RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders - BioSpace
with Several New Purchase Orders, Including Customer Reorders - Business Wire
Can RenovoRx's Premium-Priced Cancer Device Deliver on its $400M Market Potential? - Stock Titan
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery - BioSpace
RenovoRx Announces $10.9 Million Public Offering of Common Stock - Defense World
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock - Business Wire
RenovoRx (RNXT) Lands Major $12.1M Healthcare Investor Backing for Cancer Treatment Launch - Stock Titan
A better buy-in window may exist right now for RenovoRx Inc (RNXT) - SETE News
Closing Figures: RenovoRx Inc (RNXT)’s Negative Finish at 1.16, Down -20.55 - The Dwinnex
Trading Day Review: Unicycive Therapeutics Inc (UNCY) Loses Momentum, Closing at 0.57 - The Dwinnex
RenovoRx Inc (RNXT) Stock: A Year of Decreases and Increases - The InvestChronicle
RenovoRx Inc (RNXT) Stock: Tracking the Weekly Performance - The News Heater
RenovoRx 11.52M share Spot Secondary priced at $1.05 - MSN
RenovoRx (NASDAQ:RNXT) Stock Price Down 20.5% – Should You Sell? - Defense World
RenovoRx announces proposed public offering - MSN
RenovoRx Prices $12.1 Million Public Offering; Shares Decline Po - GuruFocus.com
RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement - Yahoo Finance
RenovoRx prices public offering to raise $12.1M - MSN
RenovoRx launches public stock offering By Investing.com - Investing.com Nigeria
RenovoRx Announces Pricing Of Public Offering Of About 11.52 Million Shares At $1.05/shr - Nasdaq
RenovoRx Secures Critical $12.1M Funding: Phase III Cancer Study Gets Green Light - StockTitan
Renovorx Announces Pricing Of $12.1 Million Underwritten Public Offering Of Common Stock - Marketscreener.com
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock - Business Wire
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):